marked.bio

Company

Adlai Nortye Biopharma

2 active trials that select patients by a biomarker on marked.bio.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Trials

2 of 2 trials shown

  1. Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations

    Recruiting Phase 1 Adlai Nortye Biopharma Started 2026Primary completion 2028-01 NCT07252479

    AN9025 oral capsule

    Documentation of KRAS/NRAS/HRAS mutation determined by validated local testing of tumor tissue or circulating free DNA (cfDNA) in …

    KRAS G12CKRAS G12DSolid Tumors (Phase 1), RAS Mutation

  2. A Study of AN4035 in Advanced Cancers With RAS Mutations and High CEACAM5 Expression

    Recruiting Phase 1 Adlai Nortye Biopharma Started 2026Primary completion 2028-12 NCT07686445

    Intravenous AN4035Intravenous AN4035 followed by intravenous EGFR Inhibitor.

    Documentation of KRAS/NRAS/HRAS mutation determined by a Sponsor-approved validated local testing of tumor tissue or cfDNA in a CL…

    KRAS G12CKRAS G12DSolid Tumor (Phase I), RAS Mutation, CEACAM5